Literature DB >> 8170201

Treatment of cancer-related pain: when orally administered medications fail.

T J Lamer1.   

Abstract

OBJECTIVE: To summarize the available pain-relieving interventions other than oral medications for cancer-related pain.
DESIGN: The pertinent literature is reviewed, and the various options for treating pain in patients with cancer are discussed.
MATERIAL AND METHODS: The appropriate situations for use of parenteral administration of opioids, spinal analgesia, neural blockade, and neurosurgical treatment are outlined, and the potential problems and complications associated with these techniques are described.
RESULTS: The basic approach to the management of pain in patients with cancer is to begin treatment with less potent analgesic agents early and to progress toward use of more potent pharmaceutical agents, adjuvant drugs, and invasive procedures as needed for alleviation of pain. With parenteral administration of opioids, the dosage can be adjusted rapidly, and therapy can be continued even though a patient may have gastrointestinal dysfunction. A portable ambulatory infusion pump can be used in selected patients. The major advantage of spinal opioid analgesia is the intense analgesia provided with minimal side effects. The potential complications and the availability of treatment alternatives have limited the use of neurolytic blocks, which usually provide only temporary relief of pain. In carefully selected patients with pancreatic or other upper gastrointestinal neoplasms, however, neurolytic celiac plexus and splanchnic nerve blocks are effective. Patients who fail to respond to conservative interventions may be candidates for neurosurgical procedures, such as spinal cord, cortical, or brain-stem stimulation or neuroablative operations (most commonly, cordotomy).
CONCLUSION: Cancer-related pain continues to be a major problem, and clinicians should be aware of the availability of effective treatment strategies and techniques. When orally administered medications fail to control pain or cause excessive side effects, patients should be referred to an appropriate specialist or medical center for consideration of other pain-relieving techniques.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8170201     DOI: 10.1016/s0025-6196(12)61647-4

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  6 in total

Review 1.  Transcutaneous electric nerve stimulation (TENS) for cancer pain in adults.

Authors:  Adam Hurlow; Michael I Bennett; Karen A Robb; Mark I Johnson; Karen H Simpson; Stephen G Oxberry
Journal:  Cochrane Database Syst Rev       Date:  2012-03-14

2.  Effects of Metastasis on Pain Treatment in Patients with Cancer-Related Pain: A Retrospective Study.

Authors:  Yücel Zülfi Kurşun; Fuat Yıldız; Ömer Kaymaz; Selami Ateş Önal
Journal:  Turk J Anaesthesiol Reanim       Date:  2013-08-29

3.  Intrathecal infusions for intractable cancer pain: a qualitative study of the impact on a case series of patients and caregivers.

Authors:  Philippa Hawley; Elizabeht Beddard-Huber; Cameron Grose; William McDonald; Daphne Lobb; Louise Malysh
Journal:  Pain Res Manag       Date:  2009 Sep-Oct       Impact factor: 3.037

Review 4.  Current perspectives on intrathecal drug delivery.

Authors:  Michael M Bottros; Paul J Christo
Journal:  J Pain Res       Date:  2014-11-06       Impact factor: 3.133

5.  Retrospective Analysis of Intrathecal Drug Delivery: Outcomes, Efficacy, and Risk for Cancer-Related Pain at a High Volume Academic Medical Center.

Authors:  Dawood Sayed; Forrest Monroe; Walter N Orr; Milind Phadnis; Talal W Khan; Edward Braun; Smith Manion; Andrea Nicol
Journal:  Neuromodulation       Date:  2018-02-14

6.  Intrathecal drug delivery systems for the management of chronic non-cancer pain: protocol for a systematic review of economic evaluations.

Authors:  Rui V Duarte; Tosin Lambe; Jon H Raphael; Sam Eldabe; Lazaros Andronis
Journal:  BMJ Open       Date:  2016-07-15       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.